search
subscribe by email
Twitter
-
Recent Posts
current comments
topics
- #RunningAtlas (1)
- Adaptive Sports (1)
- Atlas Venture (35)
- Bioentrepreneurship (36)
- Biotech financing (101)
- Biotech investment themes (47)
- Biotech startup advice (65)
- Boards and governance (14)
- Boston Cluster (13)
- Business Development (44)
- Capital efficiency (25)
- Capital markets (48)
- Corporate Culture (52)
- Diagnostics (2)
- Drug discovery (26)
- Exits IPOs M&As (126)
- External R&D (15)
- FDA (3)
- From The Trenches (254)
- Fundraising (14)
- General Venture Capital (45)
- Governance (2)
- Leadership (34)
- Marketing (1)
- New business models (34)
- Patients (11)
- Personal (2)
- Personalized Medicine (4)
- Pharma industry (73)
- Portfolio news (64)
- Pricing and Policy (5)
- R&D Productivity (23)
- Rare Diseases (12)
- Science & Medicine (49)
- Strategy (4)
- Talent (53)
- The Human Element (9)
- Translational research (41)
- Uncategorized (24)
- VC-backed Biotech Returns (66)
monthly archive
- November 2024 (1)
- October 2024 (2)
- September 2024 (2)
- August 2024 (2)
- July 2024 (3)
- June 2024 (2)
- May 2024 (4)
- April 2024 (4)
- March 2024 (3)
- February 2024 (2)
- January 2024 (4)
- November 2023 (3)
- October 2023 (2)
- September 2023 (1)
- August 2023 (1)
- July 2023 (2)
- June 2023 (1)
- May 2023 (1)
- April 2023 (2)
- March 2023 (3)
- February 2023 (3)
- January 2023 (1)
- December 2022 (2)
- November 2022 (3)
- October 2022 (3)
- September 2022 (1)
- August 2022 (1)
- July 2022 (2)
- June 2022 (4)
- May 2022 (2)
- April 2022 (4)
- March 2022 (7)
- February 2022 (2)
- January 2022 (2)
- November 2021 (5)
- October 2021 (1)
- September 2021 (1)
- August 2021 (2)
- July 2021 (5)
- June 2021 (3)
- May 2021 (3)
- April 2021 (6)
- March 2021 (3)
- January 2021 (2)
- December 2020 (3)
- November 2020 (1)
- October 2020 (6)
- September 2020 (2)
- August 2020 (2)
- July 2020 (3)
- June 2020 (3)
- May 2020 (3)
- April 2020 (6)
- March 2020 (6)
- February 2020 (1)
- January 2020 (1)
- December 2019 (3)
- November 2019 (2)
- October 2019 (2)
- September 2019 (2)
- August 2019 (2)
- July 2019 (1)
- May 2019 (7)
- April 2019 (6)
- March 2019 (1)
- February 2019 (6)
- January 2019 (5)
- December 2018 (1)
- November 2018 (2)
- October 2018 (8)
- September 2018 (4)
- August 2018 (1)
- July 2018 (1)
- June 2018 (4)
- May 2018 (3)
- April 2018 (4)
- March 2018 (4)
- February 2018 (6)
- January 2018 (4)
- December 2017 (3)
- November 2017 (4)
- October 2017 (6)
- September 2017 (4)
- August 2017 (2)
- July 2017 (1)
- June 2017 (5)
- May 2017 (4)
- April 2017 (1)
- March 2017 (5)
- February 2017 (2)
- January 2017 (7)
- December 2016 (3)
- November 2016 (4)
- October 2016 (3)
- September 2016 (6)
- August 2016 (5)
- July 2016 (3)
- June 2016 (6)
- May 2016 (5)
- April 2016 (4)
- March 2016 (7)
- February 2016 (5)
- January 2016 (6)
- December 2015 (6)
- November 2015 (3)
- October 2015 (4)
- September 2015 (5)
- August 2015 (3)
- July 2015 (3)
- June 2015 (4)
- May 2015 (6)
- April 2015 (6)
- March 2015 (7)
- February 2015 (7)
- January 2015 (5)
- December 2014 (4)
- November 2014 (3)
- October 2014 (7)
- September 2014 (5)
- August 2014 (5)
- July 2014 (4)
- June 2014 (6)
- May 2014 (5)
- April 2014 (5)
- March 2014 (6)
- February 2014 (4)
- January 2014 (5)
- December 2013 (3)
- November 2013 (2)
- October 2013 (4)
- September 2013 (3)
- August 2013 (1)
- July 2013 (2)
- June 2013 (2)
- May 2013 (4)
- April 2013 (2)
- March 2013 (4)
- February 2013 (1)
- January 2013 (3)
- December 2012 (3)
- November 2012 (4)
- October 2012 (3)
- September 2012 (4)
- August 2012 (3)
- July 2012 (3)
- June 2012 (4)
- May 2012 (3)
- April 2012 (2)
- March 2012 (3)
- February 2012 (3)
- January 2012 (6)
- December 2011 (4)
- November 2011 (4)
- October 2011 (3)
- September 2011 (4)
- August 2011 (3)
- July 2011 (4)
- June 2011 (4)
- May 2011 (5)
- April 2011 (8)
- March 2011 (10)
Category Archives: Drug discovery
Medicinal Chemistry In The Age Of Artificial Intelligence
August 5, 2024
By Peter Tummino, CSO of Nimbus Therapeutics, as part of the From The Trenches feature of LifeSciVC “Over the next five to 10 years, our goal is to become a company that’s leading the world in personalized medicines, a company
Neuro-Immunology: The Promise Of A Differentiated Approach To Neurodegenerative Disease
June 5, 2024
By Ivana Magovčević-Liebisch, CEO of Vigil Neuroscience, as part of the From The Trenches feature of LifeSciVC In the last decade, our industry has made great strides in combating cancer by harnessing the body’s own immune system. As it was
Pharmacology: The Anchor for Nearly Every Diligence
April 25, 2024
By Haojing Rong and Aimee Raleigh, as part of the From The Trenches feature of LifeSciVC This blog post is the second in a series on key diligence concepts and questions. If you missed the intro blog post yesterday, click
Deconstructing the Diligence Process: An Approach to Vetting New Product Theses
April 24, 2024
By Aimee Raleigh, Principal at Atlas Venture, as part of the From The Trenches feature of LifeSciVC Ever wondered what goes into diligencing a new idea, program, company, or platform? While each diligence is unique and every investor will have
Signaling Complexes: A Ripe Opportunity for Drug Development
January 3, 2024
By Jonathan Montagu, CEO of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC Signaling pathways are the intricate networks that govern cell behavior, lying at the crux of cell function. They are used by nature to
The Opportunities Waiting on Big Pharma Shelves
July 6, 2023
By Mike Cloonan, CEO of Sionna Therapeutics In 2016, following robust discovery efforts by Pfizer and others, the NBD1 domain of the CFTR protein was largely considered undruggable. They knew it was a key target – the most common genetic
The Book of Nimbus
April 27, 2023
By Jeb Keiper, CEO of Nimbus Therapeutics, as part of the From The Trenches feature of LifeSciVC Forward Nimbus Therapeutics began 14 years ago. The premise at the time was that putting computational chemistry in the primary position for new
Hacking the Human Cell – How Once ‘Un-druggable’ Proteins Became the New Frontier in Drug Development
June 21, 2022
By Jonathan Montagu, CEO and founder of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC. White Hat Hackers, sometimes called “ethical hackers,” are individuals that work to find and fix security problems in a system by
Staying Human in the Age of Artificial Intelligence
March 9, 2022
By Jonathan Montagu, CEO of HotSpot Therapeutics, and Ramy Farid, CEO of Schrodinger, as part of the From The Trenches feature of LifeSciVC. No, your next doctor will not be a robot. Nor will an algorithm cure cancer. However, AI
Hitting The Spot
November 29, 2021
By Jonathan Montagu, CEO and Co-founder of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC Today marks an important point in our journey to patients as HotSpot Therapeutics announces its $100MM Series C financing. This infusion
Selective Allosteric TYK2 Inhibitors
March 18, 2021
Family Oddball, and a New Class of Safe Oral Autoimmune & Inflammatory Disease Treatment with Blockbuster Potential By Jeb Keiper, CEO of Nimbus Therapeutics, as part of the From The Trenches feature of LifeSciVC. On day one of the JPM
The Creation Of Biotech Startups: Evolution Not Revolution
August 15, 2019
The startup paradigm for the creation and funding of new biotech companies has evolved enormously over the past two decades. Recently there’s been a pair of articles from Tech VCs about applying alternative models of company creation (here, here) to
A Decade of Discovery
May 9, 2019
This blog was written by Jeb Keiper, CEO of Nimbus Therapeutics LLC, as part of the From The Trenches feature of LifeSciVC. It is with great excitement that we at Nimbus are ringing in our 10th birthday this month. It’s
Cats And The Future Of Machine Learning In Drug Discovery
April 9, 2019
This blog was written by Jonathan Montagu, CEO and founder of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC. The predictions around the impact of artificial intelligence (AI) have been broad reaching but it’s clear that
Allostery: Realizing The Promise
March 5, 2018
This blog was written by Jonathan Montagu, CEO of Hotspot Therapeutics and Atlas EIR, as part of the From The Trenches feature of LifeSciVC. It starts off with flu-like symptoms and progresses to a perpetual low-grade fever, excessive sweating and
Human Antibody Discovery: Of Mice And Phage
May 11, 2017
The FDA recently approved Imfinzi (durvalumab) for the treatment of bladder cancer, making it the fifth new monoclonal antibody approved this year. More than twenty antibodies have been approved by the FDA since 2015. While not quite the magic bullet envisioned
Four Decades Of Hacking Biotech And Yet Biology Still Consumes Everything
April 26, 2017
Neural networks, cloud computing, deep learning, and in silico wizardry are on the cusp of disintermediating pharmaceutical drug discovery, cutting billions of billions off the industry’s cost of new drugs and reducing the time to get new medicines approved to
Exploring Company Contributions To The Origination Of New Medicines
October 13, 2016
A new FDA approval marks a major milestone in the biopharmaceutical business; relatively few biopharma companies are ever able to lay claim to having discovered, developed, or marketed a recently approved medicine. As of mid-October, the FDA has approved 17
The Virtues of Virtual – And Why We’re Devirtualizing
January 4, 2016
This blog was written by Mike Gilman, CEO of Padlock Therapeutics, as part of the “From the Trenches” feature of LifeSciVC. I stumbled into a bit of a mess a few weeks ago. It was with the best of intentions, of course.
Building The Pipeline In Small Biotech: Managing Risk And Reward
December 3, 2015
This blog was written by Ankit Mahadevia, CEO at Spero Therapeutics, as part of the “From the Trenches” feature of LifeSciVC. In my experience, looking to the outside world for new pipeline ideas isn’t just the realm of larger companies. The
Cell And Gene Therapy: An “Outside-In” Technology Evolution
November 12, 2015
The exciting renaissance in cell and gene therapy over the past five years has yielded some of the most innovative medical advances in the industry’s pipeline today. There are now multiple stories of patients getting “cured” of rare diseases, responding
Finding Redemption: Going From Bleeding Edge To Leading Edge In Drug Discovery
October 5, 2015
This blog was written by Vanessa King, CEO of Luc Therapeutics (f.k.a. Mnemosyne Pharmaceuticals), as part of the “From the Trenches” feature of LifeSciVC. High winds and cold rain certainly make a first impression – and that was even before I’d
Where Does All That Biotech Venture Capital Go?
February 9, 2015
Venture capital investing in biotech has long been hard to disaggregate: how much goes to “early stage” vs “late stage”, how much goes to CNS vs oncology, discovery vs Phase 3, etc… Today BIO’s David Thomas and Chad Wessel have
Target Practice
August 18, 2014
Every life sciences company needs to make good program choices. Big pharma creates value through smart portfolio management while small biotech companies can be defined by a single lead asset. In both cases, the opportunity cost of poor decision-making can
Talent Acquisition: Pharma Is The Lifeblood Of Biotech
May 19, 2014
Startup Biotechs need bigger drug companies for lots of things, including R&D collaborations, investments, non-dilutive funding, and eventual liquidity via M&A. The health of today’s ecosystem depends on biotech and pharma working together. But one of the most important and
Leveraging Nature’s Experiments: Mitigating Drug Discovery Risks Through Human Genetics
May 8, 2014
Extreme clinical phenotypes caused by rare genetic variations have been the basis of some of the most exciting drug targets in today’s pharmaceutical pipeline: PCSK9 in cholesterol, sclerostin in bone diseases, Nav1.7 for pain. The rare gene signatures underlying these